AbGenomics International, Inc. Regains Global Rights to AbGn-168H from ... Pr Newswire (press release) AbGn-168H preferentially induces apoptosis of late-stage activated T-cells and is being developed for the treatment of disease of the skin and other immunological diseases. Data are available from two phase one clinical trials under this development program. ... and more » Link To Article
No comments:
Post a Comment